Drug intelligence / Profile preview

mianserin + sertraline

Development stage: Preclinical
Lead developer: Organon
Modality: Small Molecules
Administration: Oral

Overview

A combination antidepressant therapy that pairs sertraline, a selective serotonin reuptake inhibitor (SSRI), with mianserin, a noradrenergic and specific serotonergic antidepressant (NaSSA). This combination is used primarily for treatment-resistant depression and PTSD, leveraging complementary mechanisms of action to potentially enhance efficacy.

Targets

SERT (Sodium-dependent serotonin transporter)HTR3A (5-hydroxytryptamine receptor 3A)ADRA1A (α1A)HTR2A (Serotonin receptor 5-HT2A)SIGMAR1 (Sigma non-opioid intracellular receptor 1)TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))ADRA2A (α2A)HTR2C (5-hydroxytryptamine 2C receptor)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on mianserin + sertraline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mianserin + sertraline.

Explore the full profile